Complete Versus culprit-Lesion only PRimary PCI Trial (CVLPRIT): a multicentre trial testing management strategies when multivessel disease is detected at the time of primary PCI: rationale and design

Damian J Kelly; Gerald P McCann; Daniel Blackman; Nicholas P Curzen; Miles Dalby; John P Greenwood; Kathryn Fairbrother; Lorraine Shipley; Andrew Kelion; Simon Heatherington; Jamal N Khan; Sheraz Nazir; Albert Alahmar; Marcus Flather; Howard Swanton; Peter Schofield; Mark Gunning; Roger Hall; Anthony H Gershlick

doi:10.4244/EIJV8I10A183

Complete Versus culprit-Lesion only PRimary PCI Trial (CVLPRIT): a multicentre trial testing management strategies when multivessel disease is detected at the time of primary PCI: rationale and design

Damian J Kelly, Gerald P McCann, Daniel Blackman, Nicholas P Curzen, Miles Dalby, John P Greenwood, Kathryn Fairbrother, Lorraine Shipley, Andrew Kelion, Simon Heatherington, Jamal N Khan, Sheraz Nazir, Albert Alahmar, Marcus Flather, Howard Swanton, Peter Schofield, Mark Gunning, Roger Hall, Anthony H Gershlick

Research output: Contribution to journal › Article › peer-review

39 Citations (Scopus)

Abstract

Primary percutaneous coronary intervention (PPCI) is the preferred strategy for acute ST-segment elevation myocardial infarction (STEMI), with evidence of improved clinical outcomes compared to fibrinolytic therapy. However, there is no consensus on how best to manage multivessel coronary disease detected at the time of PPCI, with little robust data on best management of angiographically significant stenoses detected in non-infarct-related (N-IRA) coronary arteries. CVLPRIT will determine the optimal management of N-IRA lesions detected during PPCI.

Original language	English
Pages (from-to)	1190-8
Number of pages	9
Journal	Eurointervention
Volume	8
Issue number	10
DOIs	https://doi.org/10.4244/EIJV8I10A183
Publication status	Published - 22 Feb 2013

Keywords

Prospective Studies
Endpoint Determination
Humans
Percutaneous Coronary Intervention
Research Design
Coronary Artery Disease

Access to Document

10.4244/EIJV8I10A183

Cite this

Kelly, D. J., McCann, G. P., Blackman, D., Curzen, N. P., Dalby, M., Greenwood, J. P., Fairbrother, K., Shipley, L., Kelion, A., Heatherington, S., Khan, J. N., Nazir, S., Alahmar, A., Flather, M., Swanton, H., Schofield, P., Gunning, M., Hall, R., & Gershlick, A. H. (2013). Complete Versus culprit-Lesion only PRimary PCI Trial (CVLPRIT): a multicentre trial testing management strategies when multivessel disease is detected at the time of primary PCI: rationale and design. Eurointervention, 8(10), 1190-8. https://doi.org/10.4244/EIJV8I10A183

@article{c288ace5017d46fca64926718240d9c0,

title = "Complete Versus culprit-Lesion only PRimary PCI Trial (CVLPRIT): a multicentre trial testing management strategies when multivessel disease is detected at the time of primary PCI: rationale and design",

abstract = "Primary percutaneous coronary intervention (PPCI) is the preferred strategy for acute ST-segment elevation myocardial infarction (STEMI), with evidence of improved clinical outcomes compared to fibrinolytic therapy. However, there is no consensus on how best to manage multivessel coronary disease detected at the time of PPCI, with little robust data on best management of angiographically significant stenoses detected in non-infarct-related (N-IRA) coronary arteries. CVLPRIT will determine the optimal management of N-IRA lesions detected during PPCI.",

keywords = "Prospective Studies, Endpoint Determination, Humans, Percutaneous Coronary Intervention, Research Design, Coronary Artery Disease",

author = "Kelly, {Damian J} and McCann, {Gerald P} and Daniel Blackman and Curzen, {Nicholas P} and Miles Dalby and Greenwood, {John P} and Kathryn Fairbrother and Lorraine Shipley and Andrew Kelion and Simon Heatherington and Khan, {Jamal N} and Sheraz Nazir and Albert Alahmar and Marcus Flather and Howard Swanton and Peter Schofield and Mark Gunning and Roger Hall and Gershlick, {Anthony H}",

year = "2013",

month = feb,

day = "22",

doi = "10.4244/EIJV8I10A183",

language = "English",

volume = "8",

pages = "1190--8",

journal = "Eurointervention",

issn = "1774-024X",

publisher = "EuroPCR",

number = "10",

}

Kelly, DJ, McCann, GP, Blackman, D, Curzen, NP, Dalby, M, Greenwood, JP, Fairbrother, K, Shipley, L, Kelion, A, Heatherington, S, Khan, JN, Nazir, S, Alahmar, A, Flather, M, Swanton, H, Schofield, P, Gunning, M, Hall, R & Gershlick, AH 2013, 'Complete Versus culprit-Lesion only PRimary PCI Trial (CVLPRIT): a multicentre trial testing management strategies when multivessel disease is detected at the time of primary PCI: rationale and design', Eurointervention, vol. 8, no. 10, pp. 1190-8. https://doi.org/10.4244/EIJV8I10A183

Complete Versus culprit-Lesion only PRimary PCI Trial (CVLPRIT) : a multicentre trial testing management strategies when multivessel disease is detected at the time of primary PCI: rationale and design. / Kelly, Damian J; McCann, Gerald P; Blackman, Daniel et al.

In: Eurointervention, Vol. 8, No. 10, 22.02.2013, p. 1190-8.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Complete Versus culprit-Lesion only PRimary PCI Trial (CVLPRIT)

T2 - a multicentre trial testing management strategies when multivessel disease is detected at the time of primary PCI: rationale and design

AU - Kelly, Damian J

AU - McCann, Gerald P

AU - Blackman, Daniel

AU - Curzen, Nicholas P

AU - Dalby, Miles

AU - Greenwood, John P

AU - Fairbrother, Kathryn

AU - Shipley, Lorraine

AU - Kelion, Andrew

AU - Heatherington, Simon

AU - Khan, Jamal N

AU - Nazir, Sheraz

AU - Alahmar, Albert

AU - Flather, Marcus

AU - Swanton, Howard

AU - Schofield, Peter

AU - Gunning, Mark

AU - Hall, Roger

AU - Gershlick, Anthony H

PY - 2013/2/22

Y1 - 2013/2/22

N2 - Primary percutaneous coronary intervention (PPCI) is the preferred strategy for acute ST-segment elevation myocardial infarction (STEMI), with evidence of improved clinical outcomes compared to fibrinolytic therapy. However, there is no consensus on how best to manage multivessel coronary disease detected at the time of PPCI, with little robust data on best management of angiographically significant stenoses detected in non-infarct-related (N-IRA) coronary arteries. CVLPRIT will determine the optimal management of N-IRA lesions detected during PPCI.

AB - Primary percutaneous coronary intervention (PPCI) is the preferred strategy for acute ST-segment elevation myocardial infarction (STEMI), with evidence of improved clinical outcomes compared to fibrinolytic therapy. However, there is no consensus on how best to manage multivessel coronary disease detected at the time of PPCI, with little robust data on best management of angiographically significant stenoses detected in non-infarct-related (N-IRA) coronary arteries. CVLPRIT will determine the optimal management of N-IRA lesions detected during PPCI.

KW - Prospective Studies

KW - Endpoint Determination

KW - Humans

KW - Percutaneous Coronary Intervention

KW - Research Design

KW - Coronary Artery Disease

U2 - 10.4244/EIJV8I10A183

DO - 10.4244/EIJV8I10A183

M3 - Article

C2 - 23425543

VL - 8

SP - 1190

EP - 1198

JO - Eurointervention

JF - Eurointervention

SN - 1774-024X

IS - 10

ER -